A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Incyte Corporation
Incyte Corporation
Pfizer
Teva Branded Pharmaceutical Products R&D, Inc.
Ocellaris Pharma, Inc.
CytomX Therapeutics
Pfizer
Young Adult Survivors United
Pfizer
Pfizer
NuCana plc
Mural Oncology, Inc
Aminex Therapeutics, Inc.
Astellas Pharma Inc
University of California, San Diego
National Cancer Institute (NCI)
Apexigen America, Inc.
Vanderbilt University Medical Center
Hoffmann-La Roche
Aristotle University Of Thessaloniki
Oncorus, Inc.
4D pharma plc
Asana BioSciences
Seagen Inc.
Bristol-Myers Squibb
Bristol-Myers Squibb
Amgen
Ludwig Institute for Cancer Research
M.D. Anderson Cancer Center
Genocea Biosciences, Inc.
miRagen Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
University Hospital, Ghent
miRagen Therapeutics, Inc.
Effector Therapeutics
KitovPharma
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
Eli Lilly and Company
Dartmouth-Hitchcock Medical Center
National Institutes of Health Clinical Center (CC)
CureOne
GlaxoSmithKline
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institutes of Health Clinical Center (CC)
Vanderbilt-Ingram Cancer Center
Celldex Therapeutics
The Cleveland Clinic
National Institutes of Health Clinical Center (CC)
University of Utah
Novo Nordisk A/S